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61kaka. This clinical trial was performed to determhw the
safety and clinical impact of titrated metoprolol therapy in
patients with heart failure, docwnenk~ coronary artery disease
and a low ejection fraction .
Background. Despite known cardlodepressant effects, long-
term use of beta-adrenergic antagonists appears to be beneficial in
patients with idiopathic dilated cardiomyopothy . However, this
therapy has not been critically evaluated in patients with heart
failure and coronary artery disease.
Methods. In SO patients with heart failure, known coronary
artery disease and an ejection fraction 50 .40, we examined the
impact of metoprolol therapy in a 6-month double-blind, placebo-
controlled randomh1med trial, assessing the frequency of head failure
and changes in symptoms (New York Heart P_ssula-
d on functional class), ejection fraction and exercise duration . Place-
bo-treated patients who completed 6-month follow-up studies then
underwent a trial with snetoprolol therapy (crossover group).
The idea of giving a negative inotropic agent to patients with
impaired systolic function is counterintuitive and in practice
is generally shunned . Yet, there is good evidence that
beta-adrenergic blocking agents may be beneficial in patients
with heart failure . Reports from initial uncontrolled trials
have suggested a favorable impact when titrated low dose
beta-adrenergic blockade was administered to patients with
heart failure due to dilated cardiomyopathy (14) . Subse-
quent controlled trials have been small but consistent in
showing the safety and benefit of beta-blockers, including
relatively frequent and sometimes marked clinical improve-
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Results. Metoprelol was titrated to a mean maximal dose of
87
mg/day
(range 25 to 100) without serious adverse reactions .
During double-blind therapy, use of a beta-blocker was associated
with a significant reduction in the number of hospital admissions
(4% vs. 32%, p -0 OAQ, overall improved functional class (p
0.02), increased ejection fraction (4 ± 7% (mean ± SDI compared
with 0 ± 6%, p < 0 .05) and a greater increase in exercise duration
(193 t 276 vs. 38 ± 213 s with placebo, p < 0 .01). Crossover
outcome paralleled the favorable impact seen during randomized
meteprold therapy .
Conclusions. Cautious use of titrated metoprold appears to be
safe and beneficial when added to standard heart failure therapy
in patients with dilated cardiomyopathy associated with coronary
artery disease .
(J Am Coll Cardiol 1994,23 .943-50)
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rent (5-7) . Recent reviews, editorials and a preliminary
report of a larger scale trial have all supported the potential
benefit of beta-blocker administration in patients with idio-
pathic dilated cardiomyopathy (8-16) .
Fewer investigations on the use of beta-blockers in heart
failure have included patients with coronary artery disease .
In those beta-blocker heart failure trials that include both
idiopathic and coronary artery disease-related dilated car-
diomyopathy, it has been suggested that patients with coro-
nary artery disease experience less benefit (17-19) . How-
ever, it is well known that use of beta-blockers after
myocardial infarction increases survival (20,21), with espe-
cially marked survival benefit irk patients with a history of
heart failure (22-25). Because patients with overt heart
failure were excluded from these large, randomized postmy-
ocardial infarction studies, the impact of starting beta-
blocker therapy in patients with known coronary artery
disease and overt heart failure symptoms has not been
directly addressed. Currently, clinicians routinely avoid
beta-antagonists in patients with coronary artery disease
with overt heart failure .
On the basis of promising reports in idiopathic dilated
cardiomyopathy and the intriguing subgroup analysis from
postmyocardial infarction trials, we hypothesized that beta-
0735-1097/941$7 .0,0
944 FISHER ET AL
.
	
JACC Vol . 23, No. 4
METOPROLOL IN HEART FAILURE WITH CORONARY ARTERY DISEASE
March 15, 1994
: 943-50
	 BASELINE S "Jiffia-1
STRATIFY	
EIM[on
Fraction NorepInephrine
25-40% M PWN
42S%	
000now
R &
Q72
-
CHF
(8)
6 MCAMIN
FOLLOW-UP
COMPLETED (V
M
CROSSOVER
METOPROLOL
omath t1)
Byte birnd
TOPROLOL
(20)
WrrHORAWN
Transplant (1)
It atqqnd 11)
6 MWONTIN
FOLLOW-UP
COMPLETED
?I
D"th (3)
MAINTENANCE
METOPROLOL
DMh ti)
40 W 110 MAnth
owl
fouaw month
10000 up
Figure 1. Schematic diagram of study sequence and outcome .
Number of patients in each category are shown in parentheses .
T CHF = severe exacerbation of heart failure . Transplant = cardiac
transplantation; R., stopped = study treatment discontinued (see
Results) .
blockers started at low dose and gradually titrated would be
well tolerated, reducing rather than increasing the likelihood
of severe heart failure exacerbations in patients with heart
failure and known coronary artery disease. This is the first
randomized, double-blind placebo-controlled trial of beta-
blockers to specifically examine this important cohort .
AfeNbods
Fifty patients with chronic heart failure and coronary
artery disease were entered into a 6-month double-blind trial
in which either tinted metoprolol or placebo was added to
standard heart failure therapy . Patients randomized to re-
ceive placebo who were still in stable condition after com-
pleting 6 months of placebo therapy then underwent a trial of
single-blind titrated metoprolol during the ensuing 6 months
(crossover cohort). The study design is shown schematically
in Figure 1 .
Pasmt SAX90M criteria mW baseline evaluation . Patients
referred to the University of Maryland Heart Failure Service
were considered for study if they had 1) persistent symptoms
(dyspnea on exertion, fatigue, orthopnea, paroxysmal noc-
turnal dyspnea or edema, alone or in combination) despite
treatment of heart failure for at least 3 months ; 2) docu-
mented coronary artery disease on the basis of previous
enzymatically proved acute myocardial infarction or coro-
nary angiographic evidence of 2:70% narrowing of one or
more major branches ; and 3) an ejection fraction
:540% by
radionuclide ventriculography .
Patients were excluded if they had an acute myocardial
infarction or unstable angina pectoris within 3 months,
primary valvular disease, history of any alcohol use within 6
months, coronary lesions considered suitable for intervenl tional therapy, atrioventricular block greater than first de-
gree without a functioning electronic pacemaker, rest heart
late <60 beats/min, active bronchospasm requiring mainte-
nance bronchoJilmor therapy or known active neoplastic
process. Exclusion criteria were kept to a minimum to allow
the study patients to be as characteristic as possible of the
larger population with heart failure and coronary artery
disease .
After obtaining written informed consent (approved by
the University of Maryland at Baltimore Institutional Re-
view Board, March 1986), baseline history, physical exami-
nation, laboratory studies and exercise tests were performed.
Diuretic agents, digoxin and vasodilators (angiotensin-
converting enzyme inhibitors - all but three patients) were
administered throughout the study at clinically determined
optimal doses. Patients were randomized only if the severity of
symptoms remained stable (i .e., no overt deterioration or
requirement for urgent hospital admission) for at least I month
while undergoing baseline evaluation .
For determination of plasma norepinephrine, the patient
rested in the supine position for at least 30 min with an
indwelling intravenous cannula . Blood samples were then
obtained, centrifuged and stored frozen at -70°C pending
analysis . Plasma norepinephrine was determined by radioen-
zymatic method using kits purchased from Amersham, Inc .
(intraassay variation for plasma norepinephrine of 4 .2% and
interassay variation of 7.5%) (26) .
Radionuclide ventriculography was performed using an in
vivo method for red blood cell labeling with 25 to 30 mCi of
technetium)-99m. Equiiibrium-gated blood pool images were
obtained in the 40' left anterior obliqiae projection with a 5 to
10' caudal tilt for maximal isolation of the left ventricle .
Using a high sensitivity parallel-hole c( ,Ilimator attached to a
standard Anger camera, interfaced with a commercially
available computer program, left ventricular ejection fra ,>
tion corrected for background was determined . Results were
visually reviewed by the nuclear medicine staff who re-
mained unaware of the specific protocol treatnicnt .
Exercise capacity was measured with graded maximal
bicycle exercise and scored as the total duration of exercise
on symptom-limited testing . Bicycle tests were started at
20 W, except for 17 of the more severely debilitated or
symptomatic patients who initiated exercise with no added
resistance for the 1st 3 min . Serial 3-min stages were graded
in 10-W increments. Before randomization, bicycle testing
was done twice (once to familiarize the patient with the
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procedure and the second time to establish the baseline).
The 6-month test for each patient was a single measurement .
Study entry occurred between April 1986 and March
1992. To achieve comparable groups, the 50 patients were
categorized on the basis of ejection fraction (25% to 40% or
<25%) and plasma norepinephrine (<600 vs . X600 pg/ml) for
stratified randomization (27,28) .
Treatment protocol. During double-blind therapy, doses
of diuretic agents, vasodilators and digoxin were adjusted as
needed. Ciba-Geigy Pharmaceuticals provided the meto-
prolol, along with matching placebo tablets . Study medica-
tion was titrated (as tolerated) at weekly intervals from 6 .25
to 12 .5 mg twice a day to 12 .5 mg three times a day to 25 mg
twice a day to 25 mg three times a day and to 50 mg twice a
day . Dose titration was deferred or stepped back if symp-
toms increased or heart rate/blood pressure decreased ex-
cessively (rest heart rate <50 bewslin or systolic blood
pressure <80 mm Hg). The highest tolerable dose of study
medication achieved after a maximum of 8 weeks of titration
was maintained for the duration of double-blind treatment .
Thereafter, patients were seen at least once monthly until
completion of 6 months of study treatment or the occurrence
of death or a severe exacerbation of heart failure (defined as
an episode that necessitated admission to an intensive care
unit and administration of intravenous vasodilators or iso-
tropic agents) . All decisions with regard to need for intensive
care and parenteral therapy were made by staff independent
of the study team .
Follow-up studies were performed after 6 months of
treatment, before breaking the double-blind code . Death,
study withdrawal or severe heart failure exacerbation pre-
cluded obtaining complete follow-up studies after 6 months
of double-blind therapy in I I patients (Fig . 1). Placebo-
treated patients in stable condition then began 6 months of
titrated single-blind metoprolol therapy (crossover cohort)
using similar weekly dose titration . Follow-up studies were
repeated at the end of 6 months of rtietoprolol therapy .
Patients who remained in stable condition after 6 months of
randomized metoprolol therapy were continued on beta-
blocker therapy (single-blind maintenance group) .
Data analysis . In patients who completed double-blind
therapy, New York Heart Association functional class,
ejection fraction and exercise duration at the completion of 6
months of therapy were compared with baseline measures to
yield a net change for each variable in each patient . To be
categorized as improved or deteriorated, these changes had
to exceed predefined, arbitrary values (change in functional
class of one grade or more, change in ejection fraction ?3%
and change in exercise time of at least 60 s) .
All values are expressed as mean value ± SD . Baseline
measures for placebo and metoprolol therapy were com-
pared using two-tailed, nonpaired t tests or Wilcoxon rank-
sum testing (for nonparametrically distributed values) . The
chi-square statistic with the Yates correction for continuity
was used to compare categoric baseline features and the
frequency of severe heart failure exacerbations in the random-
Table 2. Comparison of Baseline Characteristics of Randomized
aaeatment Groups
FISHER ET AL
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*There were no statistically significant differences between the two
groups at baseline
. Values presented are mean value ± I SD or number (%)
of patients . ACE inhibitor = angiotensin-converting enzyme inhibitor they
.
apy ; BP = blood pressure ; CABG = coronary arl , ay bypass graft surgery ;
COPD = chronic obstructive pulmonary artery disease ; F = female ; HR =
heart rate ; M = male ; Ml = myocardial infarctions ; NYHA = New York Heart
Association functional class
; PICA = percutancous transluminal coronary
angioplasty .
ized cohort . Baseline measures were compared with posttreat-
ment results using two-tailed paired i tests . Changes in func-
tional class, ejection fraction and exercise duration in the
placebo- and metoprolol-treated groups were compared to
determine the number of patients in an improved, stable or
deteriorated condition using chi-square analysis . Changes in
ejection fraction were compared between the placebo and
metoprolol groups using a nonpaired t test . Changes in exercise
times were compared using the Wilcoxon rank-sum test
. Sta-
tistical significance was accepted when p :s 0 .05 .
Results
There were no statistically significant differences in base-
line characteristics of the two randomized groups (Table I) .
The groups were well matched in terms of functional class,
age, exercise duration and the two stratifying variables
(ejection fraction and plasma norepinephrine) .
Addition of initial low dose beta-blocker to optimized
standard therapy caused no serious adverse reactions
. The
Metoprolol
(n = 25)
Placebo
(n = 25)
Age (yr) 63±8
63 ± 10
Duration (mo) 31 t 26
33 :t 31
Gender (M/F)
25/0 2312
Attial fibrillation 5(25)
3 (15)
Previous MI
19 (76)
18(72)
Previous CABG/PTCA
11(44) 13(52)
Diabetes mellitus 3 (i2)
3 (12)
COPD
3(12)
7(28)
Peripheral artery disease
6 (24) 4(16)
Previous alcohol use 8 (32)
8 (32)
Furosemide (mg/day) I19 ± 86 115 ± 91
ACE Inhibitor
24 (%) 23(92)
Digoxin
23(92) 25 (100)
NYHA functional class
II
10 10
III
12 1
IV 3
4
Rest HR (min - ') 82 :t 92 66 ± 12
Rest OP
Systolic tmrn Hg) 117 t 25 117 ± 19
Diastolic (mm Hg) 73 t 10 74 ± 11
Third heart sound 10 (40) 6(24)
Mean ejection fraction 0 .22 t 0 .8 0.23 ± 0 .9
Mean duration of exercise (s) 482 ± 374 462 ± 461
Serum creatinine (mg/dl) 1 .6 ± 0 .5 1 .7 ± 0 .6
Plasma norepinephrine (pg/ml) 499 ± 508
479 ± 269
9"
	
FISHER ET AL.
MFrOlTROLOL IN HEART FAILURE WITH CORONARY ARTERY DISEASE
MAk 2. Comparison of Changes in End Point Measures During
Double-BIW Therapy*
'Chatwn in outcome measures
during randomized, double-blind therapy
(fivm baseline to 6 months or when available at the time of withdrawal in
patients with severe exacerbations,
poked t tests). In the placebo cohort, the
lad measures were nnot siguh%
;antly dAknmt thas baseline; with the meto-
, the results at 6 months showed a significant
improvement in
each measure compared with baseline (p :5 0.01) . tChi-squm
analysis.
$Nonpaind t test . §Wilcoxon
signed rank tesc
mean maximal dose of metoprolol tolerated during double-
blind therapy was 87 ± 25 mg/day (rangc 25 to !00). Of the
six patients who did not achieve the target maximal dose of
101 mg/day, three had dose titration stopped because of rest
heart rate <60 beats/min, one developed increased leg
claudication, and one experienced a severe heart failure
exacerbation 3 weeks after starting metoprolol therapy . Two
patients in the metoprolol cohort were withdrawn from
double-blind therapy after having reached the maximr I dose
without problem. One had study treatment inadvertently
discontinued at the time of noncardiac surgery, and the other
underwent cardiac transplantation while in clinically stable
condition .
As shown in Figure 1, durhig : 6 months of double-blind
therapy, eight patients randomized to receive placebo (32%)
required urgent admission for parenteral therapy with an
intravenous vasodilator or inotropic agent, whereas only one
metoprolol-treated patient (47b) had a similar severe heart
failure exacerbation (p < 0 .05 compared with placebo) .
Furthermore, no other metoprolol-treated patient had any
hospital admissions or emergency room visits for increased
heart failure during double-blind therapy or over the ensuing
6 months of maintenance beta-blacker therapy.
The changes in functional class, ejection fraction and
exercise duration are shown in Table 2 and Figures 2 to 4 .
Whether examined in terms of mean change of each variable
or the frequency of deterioration versus improvement or
stability, each outcome measure was better in the beta-
blocker cohort. As evident in Figure 2, symptomatic im-
provement (by at least one functional class) was more
frequent with beta-blacker than placebo therapy (15 patients
[60%] vs. 6 patients (241%1, respectively, p < 0.05). In
addition to the eight patients who had profound clinical
exacerbations, five other placebo-treated patients had an
increase in functional class when they completed blinded
therapy. Thus, more than half of the placebo group (52%)
had symptomatic deterioration despite continued standard
heart failure treatment . Heart failure medications were in-
creased during double-blind therapy in 14 of the placebo-
JACC Vol. 23, No . 4
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Flpre 2. Changes in New York Heart Association functional class
during randomized and crossover therapy. Parentheswi indicate
number of patients in each group for whom changes in functional
class could be assessed. Ba smeWgmnewnts represent percent of patients
in each group (condition improved by one or more functional class,
unchanged functional class or deteriorated by one or more func-
tional class). Statistical difference between metoprolol and placebo
groups is shown (chi-square analysis) .
treated patients (56%) and in 6 of the metoprolol-treated
patients (24%) (p = 0 .07). In all but one patient this change
was an increase in diuretic agent dose, sometimes transient .
Mean ejection fraction increased by an average of 4% in
patients randomized to metoprolol therapy (p < 0.01), but
there was no change in mean ejection fraction in patients
who received placebo (p < 0 .05, placebo vs . metoprolol
ps). Figure 3 shows the pattern of ejection fraction
change in patients completing 6-month follow-up studies,
along with patients from each cohort who had intervening
events that precluded obtaining a follow-up ejection fraction .
Mean bicycle exercise duration increased significantly in
patients treated with a beta-blocker (p < 0.01) but was
unchanged during placebo therapy (p < 0 .01, placebo vs .
metoprolol groups). Like the changes in functional class and
ejection fraction, bicycle exercise duration deteriorated less
frequently during beta-blocker therapy than with placebo
(p < 0.05) (Fig . 4) .
Overall mortality during the randomized phase was 6%
(three deaths), Two of the eight placebo-treated patients
with severe heart failure exacerbations died, one during this
admission and one soon after discharge . One death occurred
in the randomized metoprolol cohort . The patient withdrawn
from evaluation because of inadvertent discontinuation of
study medication at the time of an admission for elective
surgery died of a perioperative septic complication . Of note,
before this admission, this patient's symptoms had improved
during metoprolol therapy .
Placebo Metoprolol
Placebo
VS .
Meloprolol
(p Value)
NYHA functie' ' class -0.1 ± 0 .8 -0
.6 ± 0 .7 0.02t
Ejection fractw .- A O :t 6
+4 ± 7 <0.05t
Exercise duration (s) +38 ± 213 +193 ± 276
<0.015
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Figure 3 . Changes in ejection fraction for all patients who com-
pleted 6 months of randomized or crossover metoprolol therapy .
The two patients with exacerbation of heart failure for whom
follow-up ejection fractions were available before the start of
parenteral inotropic therapy are also included . Parentheses indicate
the number of patients in each group . Bar segments represent
percent of patients in each group . Statistical difference between the
metoprolol and placebo groups is shown (chi-square anJysis) .
Crossover group . Of 25 patients randomized to receive
placebo, 17 were given single-blind titrated metoprolol after
6 months of placebo therapy . Crossover outcome closely
parallels results seen during randomized metoprolol treat-
ment (Fig . 2 to 4). The functional class was stable or
improved in 15 patients (88%) ; ejection fraction improved in
I I patients (65%) ; and exercise duration increased in 50% of
patients with available follow-up exercise results . There was
a 94% event-free survival during the 1st 6 months of meto-
prolol therapy, with the single death related to a stroke .
Combining randomized metoprolol and crossover cohorts . a
total of 42 of the original 50 patients received at least initial
treatment with a beta-blocker, and 37 (88%) were alive at I
year after start of beta-blocker therapy . Of the five deaths,
progressive heart failure and sudden cardiac death ac-
counted for one each, whereas three other deaths were
related to noncardiac events (stroke, sepsis and metastatic
cancer) .
Changes in ejection fraction. Serial ejection fractions are
plotted in Figure 5. We examined the frequency of marked
improvement in ejection fraction, defined as an increase in
ejection fraction &% (i .e ., exceeding I SD of the change
observed during placebo therapy) . Marked improvement
occurred in only one patient during placebo therapy (4%),
whereas increases of a8% occurred in 10 (26%) of 38
patients who completed 6 months of long-term beta-blocker
ESHER ET AL
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PATIENTS
I
11111111
L -
IMPROVED
A 60 sec
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TER RATE
160 sac
Qae I Mys in exercise duration during randomized and
crossover therapy. Parentheses indicate the number of patients 'n
each group who had both pretreatment and posttreatment exercise
tests . Bar segments represent the percent of patients in each group .
Statistical difference between the randomized metoprolol and pla-
cebo groups is shown,
therapy (p = 0.05) . During the succeeding 6 months of
therapy (maintenance), an additional four patients (11%) met
this criterion for marked improvement .
Discussion
This is the first trial to specifically examine the impact of
beta-blockers in heart failure associated with coronary ar-
tery disease . Our results reinforce previous favorable obser-
vations from uncontrolled and controlled studies of dio-
pathic dilated cardiomyopathy (1-4,16,29-32) and extend
these findings to patients with coronary artery disease .
Compared with placebo, use of metoprolol reduced the
number of hospital admissions for heart failure exacerba-
tions and led to more frequent improvement in symptoms,
increased ejection fraction and prolonged exercise duration
and also tended to reduce the need for increased doses of
other heart failure medications . More than half of the place-
bo-treated patients had increased symptoms during random-
ized therapy, whereas nearly all of the metoprolol cohort had
either stable or diminished symptoms .
Despite known direct negative inotropic effects, all 42
patients in the randomized and crossover groups safely
tolerated initiation of titrated metoprolol . Other beta-blocker
heart failure trials suggest that intolerance may occur even
with small initial doses in -10% to 15% of patients (13) . A
29% incidence of intolerance to a single 12 .5-mg test dose of
carvedilol (a beta-blocker with vasodilator properties) was
reported (33), leading the investigators to suggest that future
948
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Figure S . Changes in ejection fraction are plotted for each patient
Who
had both a baseline and follow-up ejection fraction . Mean
ejection fraction (±! SD) is shown for each group before and after
therapy . Solid circles represent those patients who either died or had
early ibliow-up ejection fraction due to a severe heart failure
exacerbation (death shown as follow-up ejection fraction of 0, but
these values were not included in calculation of mean follow-up
ejection fraction) . Patients whose ejection fraction increased by
4% are indicated by solid squares with bold line. Changes in the
crossover cohort are plotted starting at 6 months (i .e ., before
beta-blocker therapy) and at 12 months (i .e ., after 6 months of
metoprolol therapy).
carvedilol trials should use a lower initial dose . Perhaps the
paucity of adverse effects observed in our patients reflects
the very low initial dose of a cardioselective beta-blocker,
careful prestudy optimization of angiotensin-converting en-
zyme inhibitor, diuretic agent and digitalis doses and the
titration of these medications as needed .
During double-blind therapy, only one metoprolol-treated
patient (0) experienced marked worsening of heart failure
symptoms, whereas 32% of the placebo-treated patients had
severe exacerbations (p < 0.05). The relatively high fre-
quency of severe heart failure exacerbations during 6 months
of placebo therapy reflects an older, chronically ill patient
group (predominantly functional class III and IV despite
digoxin, vasodilators and a mean daily furosemide dose
>100 mg). As shown in Table 2 and Figures 2 to 4, there
were also significant differences in the key end points
(functional class, ejection fraction and exercise duration)
between the two randomized groups, whether characterized
by mean change or by frequency of outcome category . Much
larger trials are needed to define the effect of beta-blockers
on mortality in chronic heart failure, with or without under-
lying coronary artery disease .
Although there is a well-recognized role for beta-blockers
in decreasing ischemia, it has been suggested that beta-
antagonists may be less beneficial in heart failure associated
with coronary artery disease than in patients with idiopathic
dilated cardiomyopathy (17,32,33)
. Given the chronicity of
coronary artery disease and the relatively large areas of
fibrosis that may be associated with previous myocardial
infarctions, it has been assumed that marked increases in
ejection fraction are not possible in patients with coronary
artery disease who receiv,. jeta-blockers . Biopsy data from
studies of idiopathic cardiomyopathy suggest that the extent
and type of fibrosis predicts the likelihood of increased
ejection fraction with beta.-blocker therapy (31) . Neverthe-
less, our results indicate that definite symptomatic and
functional improvement is common and is often accompa-
nied by an unexpected degree of reversibility of left ventric-
ular dysfunction . The mean increase in ejection fraction was
4% during beta-blockade, but 10 (26%) of 38 patients had
marked improvement (>8%) . An additional 11% showed
progressive improvement during the next 6 months, yielding
an overall frequency of marked improvement of 37% (Fig .
5), Predictably, such improvement was rare (one patient,
4%) in the placebo cohort (p = 0.05) .
Crossover and maintenance groups. The crossover cohort
(17 patients Who completed placebo therapy and received
single-blind metoprolol therapy) is not directly comparable
to the original placebo-treated group at baseline, having been
"selected" by a more prolonged, stable course of standard
therapy. However, on average, symptoms, ejection fraction
and exercise duration in this group had not changed during
placebo therapy. Although uncontrolled, and hence less
definitive than placebo-controlled findings, these crossover
observations provide additional confirmation of the safety of
starting low dose metoprolol therapy in patients with coro-
nary artery disease with symptomatic heart failure . Further-
more, improvement in functional class, ejection fraction and
exercise duration closely paralleled the findings during ran-
domized therapy .
In previous heart failure trials in which withdrawal of
beta-blockers was attempted, relatively frequent and
sometimes fatal deterioration was noted (6,34) . Hence,
metoprolol-treated patients continued beta-blocker therapy
(maintenance group) . The clinical improvement and low
likelihood of heart failure exacerbations seen in the 1st 6
months of study were sustained, with late or progressive
increase in ejection fraction in some patients (Fig . 5).
Mechanism of benefit. A number of hypotheses have
been proposed to explain the unexpectedly positive impact
of beta-antagonists in heart failure (5-15,35). The so-called
compensatory increase in sympathetic activity, characteris-
tic of advanced heart failure, may actually contribute to the
progressive myocardial damage . Studies in animal models
using intact hearts and cell cultures, as well as clinical
observations in patients with cardiomyopathy due to pheo-
chromocytoma, confirm the adverse impact of high levels of
catecholamines (36-39) . In heart failure, catecholamines
may cause direct injury or mediate their adverse effects by
increasing metabolic demand on an already energy-starved
myocardium (40). Catecholamines hiso may compromise
coronary blood flow by shortening diastole (increased heart
rate) and by causing vasoconstriction. It is now well recog-
JACC Vol. 23, No . 4
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nized that successful revascularization may yield marked
improvement in some patients with depressed ventricular
function. Increased coronary flow presumably leads to re-
covery of stunned or hibernating myocardium (41-43). It is
possible that beta-blocker-induced alteration of the supply/
demand imbalance can mediate similar recovery in patients
with congestive heart failure .
Beta-antagonist-mediated upregulation of beta-receptors
may also contribute to improved left ventricular function
(4,35) . Although increased receptor concentration and activ-
ity may explain improved responsiveness to dobutamine
administration, they are a less satisfactory explanation for
increased ejection fraction at rest (4,11,13,32) . Furthermore,
the time course of receptor upregulation (hours to days) does
not parallel the much slower improvement in ventricular
function (11, 13). In patients with idiopathic dilated cardio-
myopathy there is no correlation between the degree of
improvement in ejection fraction and the changes in recep-
tors (44) .
Previous studies. Pooled results from multiple previous
beta-blocker trials showed a mean increase in ejection
fraction of 7% in 190 patients (treated for I to 17 months)
(13) . In a small group of patients with coronary artery
disease and heart failure, use of carvedilol yielded an aver-
age increase in ejection fraction of 4% in the cohort that
tolerated the agent (33) . The mean increase in ejection
fraction of 4% in Pin- patients treated with metoprolol for 6
months is consistent w= i lt these reports . Our experience also
confirms earlier suggestions that a relatively long duration of
treatment may be needed to assess the potential benefit of
long-term beta-blocker therapy in patients with heart failure
(3,29) .
Limitations of the present study. The size and duration of
this placebo-controlled trial permitted examination of differ-
ences in symptomatic and functional changes but not mor-
tality . Exercise evaluations in this trial did not include
oxygen consumption or require specific degree of reproduc-
ibility at baseline for entry . However, the magnitude of
difference in exercise duration between the placebo and
metoprolol cohort was significant . Lack of stringent baseline
reproducibility would tend to reduce not increase the likeli-
hood of detecting a statistical difference . There was no
systematic assessment for the presence or degree of revers-
ible myocardial ischemia before study treatment . We cannot
comment on whether ischemia accounts for any of our
observations, but it should be noted that no patient had
clinical evidence of frequent or unstable ischemic symptoms
during randomized or crossover treatment . This was not
designed as a complete crossover trial because of previous
reports of major adverse reactions when patients with di-
lated cardiomyopathies were withdrawn from beta-blocker
therapy (6,34) . Finally, this study cohort was almost exclu-
sively male, reflecting a large component of recruitment
from the Department of Veterans Affairs Medical Center in
Baltimore and may not be applicable to women .
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Relevance of the present study. Our study patients is
wide range of coronary artery disease severity, including
60% who were in functional class III or IV despite relatively
high doses of diuretic agents along with digoxin and vasodi-
lators (primarily angiotensin-converting enzyme inhibitors) .
The well known propensity for compromised patients with
heart failure to experience periodic severe exacerbations
was evident . The primary focus of analysis was the double-
blind randomized component, but the nearly identical pat-
tern of outcome in the postplacebo crossover cohort rein-
forces the validity of the observation that beta-blockers
favor a propensity to improve rather than deteriorate .
Conclusions . In this randomized, double-blind trial, pa-
tients with chronic heart failure associated with reduced
ejection fraction and documented coronary artery disease
tolerated initiation of titrated metoprolol well . Long-term
beta-blocker therapy resulted in improvement of symptoms,
left ventricular function and exercise duration as well as
reduced likelihood of severe exacerbation compared with
the placebo-treated cohort . Future studies of titrated beta-
blockade in patients with heart failure and documented
coronary disease should include larger scale survival trials as
well as studies to characterize possible mechanisms by
which marked increases in ejection fraction may occur with
beta-adrenergic antagonists . Until larger trials are completed
and satisfactory low dose formulations become available,
the use of beta-blockers remains a promising but still exper-
imental form of treatment for congestive heart failure asso-
ciated with coronary artery disease .
E. Siegal, MD, S . Fisher, C . Krichten, RN, MS, M . Cines, RN, D. Gnegy,
MD, G. Frank, RCVT (deceased), L . Greshani, LPN, K . Hagin, G . Shayne,
PAC and S. Austin, PAC contributed to this study . R . Vogel, MD and J .
}Castor, MD provided support for the staff involved in this project . J . R .
Hebel, PhD and E . Dax, MD assisted in the initial design of this study . The
University of Maryland medical house staff and our referring physicians also
helped support this project .
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